Hoffmann-la Roche Inc.

Genentech, Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Pierre Goldbach

Lionel Vedrine

Hanns-Christian Mahler

Olaf Grassmann

Rene Trussardi

Heather L Flores

René Trussardi

Kewei Yang

Michael Hennig

Baboo Dushyantsingh Goordyal

Thomas Pfister

Florian Wildenhahn

Anke Diederich

Mathieu Rigollet

Ines Sauer

Ivy Lin

Frank Bamberg

Edward Schwarb

Elisabeth Schaible

Robert Müller

Robert Mueller

André Bubendorf

Andre Bubendorf

A syringe () has a longitudinal body () with an interior () in which a pharmaceutical substance is arranged, a needle connected to one longitudinal end of the body () and a rigid needle shield () encasing the needle. The rigid needle shield () is essentially water vapour tight. The syringe () according to the invention allows for preventing needle clogging and, thus, proper provision of pharmaceuticals, particularly by subcutaneous, intramuscular or ocular injection.

Syringe and method of preparing syringe

The present invention relates to polymorphic forms of (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester phosphate, which is a potent inhibitor of viral neuraminidase.

Polymorphic forms of oseltamivir phosphate

The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.

Parenteral bisphosphonate composition with improved local tolerance

Growing community of inventors

Rixheim, France

Pierre Goldbach